Patents Assigned to QIAGEN GmbH
-
Patent number: 10648031Abstract: The present invention is directed to novel methods and kits to be employed for preparing adapter-ligated amplicons or a sequencing library of a target DNA, respectively.Type: GrantFiled: August 21, 2015Date of Patent: May 12, 2020Assignee: QIAGEN GmbHInventors: Nan Fang, Dirk Loeffert
-
Patent number: 10633697Abstract: The invention is in the field of regulation of enzymatic activity in nucleic acid modifying reactions. It describes a method of regulating enzymatic activity by adding chelating agents to the reaction composition and exploits the fact that both the binding of divalent cations to these chelating agents and the pH of commonly used buffers is temperature dependent. PCR experiments that are hampered by non-specific side products can be regulated such that the target sequence is amplified in a more specific manner.Type: GrantFiled: January 15, 2015Date of Patent: April 28, 2020Assignee: Qiagen GmbHInventors: Alexander Azzawi, Ralf Peist
-
Patent number: 10634588Abstract: The present invention relates to a reagent for the disruption of cell material, containing an internal standard that is completely integrated into the reagent for control and evaluation of the completeness of disruption of the cell material and subsequent steps, comprising a step selected from sample preparation, extraction, enrichment, isolation, purification, reverse transcription, amplification and detection of the cell components obtained from the disrupted cells, or a combination of a plurality or all of these steps.Type: GrantFiled: September 23, 2011Date of Patent: April 28, 2020Assignee: QIAGEN GmbHInventors: Dirk Heckel, Katharina Beller
-
Patent number: 10614571Abstract: System and method for distinguishing at least one first object from at least one second object in a plurality of digital images is provided. The at least one first object having received at least one molecule comprising genetic information, the at least one second object not having received a molecule comprising genetic information. The at least one molecule is configured to receive one of a plurality of fluorescent compounds in each of a plurality of cycles. The digital images being determined by an optical imaging system during emission of electromagnetic radiation by the fluorescent compounds, wherein the plurality of digital images comprises a plurality of series of images, each image of a series referring to the emission spectrum of a respective fluorescent compound and wherein the series of images is repeatedly taken for each of the plurality of cycles.Type: GrantFiled: December 9, 2016Date of Patent: April 7, 2020Assignee: QIAGEN GmbHInventors: Thomas Unterer, Guido Schuster
-
Patent number: 10538809Abstract: Short tandem repeat (STR) markers are genetic elements that are frequently used in the fields of forensic analysis, paternity determination and detection of genetic diseases and cancers. Such analysis involves the amplification of STR loci. Technically, this can be challenging due to sequence variations in the flanking regions of the locus. In the case of SE33, previous amplification efforts have failed. The present invention describes a set of primers for the amplification of SE33 and a method for the analysis of the presence and/or level of SE33, also in combination with other STRs.Type: GrantFiled: January 28, 2015Date of Patent: January 21, 2020Assignee: QIAGEN GMBHInventors: Daniel Müller, Sascha Strauss
-
Patent number: 10514330Abstract: The present invention refers to a device, comprising a hollow body having at least one open end comprising at least one solid matrix binding, adsorbing, absorbing, chelating or retaining compounds which are not desired in a sample and preferably at least one barrier which is non-permeable for liquids and solids under ambience conditions, however, becomes liquid-permeable by applying an external force to the barrier, the use of such a device for isolating or purifying a biomolecule from a sample, a method for preparation of the device and a method for isolation or purification of any biomolecule using said device.Type: GrantFiled: July 13, 2011Date of Patent: December 24, 2019Assignee: QIAGEN GmbHInventors: Vera Holländer, Markus Müller, Karin Schulte
-
Patent number: 10501783Abstract: The present invention relates to methods and uses for the detection or quantification of newly-synthesized double-stranded target nucleic acid molecules in a sample during quantitative real-time polymerase chain reaction (qPCR) amplification. According to the invention, an intercalating dye recognizing double-stranded DNA molecules with higher affinity than single-stranded DNA molecules and a fluorophore-labeled oligonucleotide-probe being sequence specific for a target nucleic acid molecule are simultaneously employed, thus enabling quantification a specific target and total amount of a mixed nucleic acid population, and enabling assessing the cause of suboptimal PCR performance.Type: GrantFiled: December 9, 2014Date of Patent: December 10, 2019Assignee: QIAGEN GMBHInventors: Nan Fang, Andreas Missel, Katja Heitz, Holger Wedler
-
Patent number: 10458998Abstract: Device for sample processing, particularly sample conditioning as well as for the preparation and/or optionally for implementing a sequential process for an analyte from a biological sample, said device comprising a module for receiving and/or outputting at least one sample vessel or process vessel, a module for transporting a process vessel, a module for sample conditioning and a module for initiating a sequential process for an analyte. The modules are divided into at least two units that each possesses a control system, and which are connected through a first data bus.Type: GrantFiled: July 27, 2007Date of Patent: October 29, 2019Assignee: QIAGEN GMBHInventors: Magnus Alfredsson, Konstantin Lutze, Thomas Deutschmann, Patrick Widler, Samuel Farner, Ulf Friederichs, Axel Bützer, Jürg Aeschbacher, Bruno Walder
-
Patent number: 10407713Abstract: The present invention provides a special reagent for the pretreatment of sample materials. The pretreatment with the reagent according to the invention enables the isolation of nucleic acids by a uniform method from very diverse sample materials, in particular different bioprocess samples, even if the nucleic acids are only present in small amounts in the sample materials. The reagent used for the pretreatment comprises, as key component, at least one compound comprising an amino group. The invention further relates to methods of purification of nucleic acids, in which the sample material is pretreated correspondingly, and suitable kits.Type: GrantFiled: July 4, 2012Date of Patent: September 10, 2019Assignee: QIAGEN GmbHInventor: Peter Porschewski
-
Patent number: 10400288Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.Type: GrantFiled: February 5, 2016Date of Patent: September 3, 2019Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbHInventors: Anni Rønfeldt Thomsen, Jacob Christian Fredsøe, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
-
Publication number: 20190259137Abstract: Method and system for compensating intensity biases in a plurality of digital images. Each digital image of the plurality of digital images contains a plurality of objects and each of the plurality of objects is configured to receive at least one molecule comprising genetic information, wherein the at least one molecule is configured to receive one of at least a first fluorescent compound and a second fluorescent compound. A first digital image of the plurality of digital images is taken by an optical imaging system during emission of electromagnetic radiation by the first fluorescent compound, and a second digital image of the plurality of digital images is taken by the optical imaging system during emission of electromagnetic radiation by the second fluorescent compound.Type: ApplicationFiled: October 20, 2017Publication date: August 22, 2019Applicant: QIAGEN GmbHInventors: Thorsten ZERFASS, Maiko LOHEL, Fernando Carrillo OESTERREICH
-
Patent number: 10376887Abstract: Closing arrangement for a cap of a tube in a carrier, wherein the arrangement comprises at least a first, a second and a third moveable engagement member, the first member being adapted to induce a first part of the cap rotation and the second member being adapted to induce a second part of the cap rotation and the third member being adapted to induce a third part of the cap rotation for closure.Type: GrantFiled: April 9, 2014Date of Patent: August 13, 2019Assignee: Qiagen GMBHInventors: Bruno Walder, Sasa Lazevski, Kurt Stark
-
Patent number: 10358681Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.Type: GrantFiled: February 26, 2016Date of Patent: July 23, 2019Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbHInventors: Anni Rønfeldt Thomsen, Helle Kristensen, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
-
Patent number: 10329553Abstract: The present invention provides a method for isolating RNA including small RNA having a size of 200 nt or less from a sample, comprising the following steps: a) providing a composition comprising RNA and a chaotropic agent; b) adding alcohol; c) incubating the mixture for at least 2 min; d) adding additional alcohol to the mixture to adjust the overall alcohol concentration in the mixture to ?50%; e) binding RNA contained in the mixture to a nucleic acid binding solid phase; f) optionally washing the bound RNA; g) optionally eluting RNA from the solid phase. Due to the step-wise addition of alcohol, the overall RNA yield and the yield of small RNA is improved.Type: GrantFiled: September 3, 2013Date of Patent: June 25, 2019Assignee: QIAGEN GmbHInventors: Martin Schlumpberger, Stefanie Schröer, Vera Holländer
-
Patent number: 10323273Abstract: The present invention relates to methods and uses where a combination of (i) an enzyme exhibiting 5??3? exonuclease activity and specifically degrading 5?-phosphorylated strands of double-stranded nucleic acids is used, and (ii) one or more primer pair(s), each primer being 5? phosphorylated, in a method comprising at least a first and a second amplification reaction of a first and a second template, respectively, for preventing contamination of the second amplification reaction with amplification products of the first amplification reaction, as well as novel methods and kits using the combination. Also, the present invention relates to kits comprising the enzyme and either 5?-phosphorylated primers or a polynucleotide kinase.Type: GrantFiled: May 28, 2015Date of Patent: June 18, 2019Assignee: Qiagen GmbHInventors: Nan Fang, Dirk Loeffert, Christine Runde
-
Patent number: 10273470Abstract: The present invention pertains to a method for isolating RNA, including small RNA from a RNA and DNA containing sample, wherein the sample is lysed and the optionally further processed lysate is incubated with a DNase to degrade DNA prior to purifying the RNA from the optionally further processed lysate. It was found that performing the DNase digest prior to isolating the RNA from the lysate has considerable advantages.Type: GrantFiled: February 25, 2011Date of Patent: April 30, 2019Assignee: QIAGEN GmbHInventors: Vera Holländer, Gabriele Christoffel
-
Patent number: 10233508Abstract: The present disclosure provides methods, compositions and devices for isolating virus particles and/or viral nucleic acids from body samples that were stabilized using a stabilizing composition comprising a formaldehyde releaser agent.Type: GrantFiled: August 21, 2013Date of Patent: March 19, 2019Assignee: QIAGEN GmbHInventors: Martin Horlitz, Markus Sprenger-Haussels, Annabelle Schubert, Uwe Oelmüller
-
Patent number: 10227378Abstract: The present invention pertains to a method for loading a crystallization device and for manufacturing a crystallization device comprising multiple receptacles with a pre-defined amount of at least one matrix-forming compound capable of forming a crystallization matrix for a membrane protein, said method comprising the following steps: a) Modifying the state of aggregation of said at least one matrix-forming compound to a fluidic state which allows dispensing said at least one matrix-forming compound, and b) dispensing a defined amount of said at least one matrix-forming compound into at least one receptacle of the crystallization device, wherein said dispensed matrix-forming compound solidifies within said receptacle. Thereby prefilled crystallization devices are obtained which can be used as consumables in particular in automated crystallization processes. Also provided are protein crystallization methods using respectively prepared crystallization devices.Type: GrantFiled: May 2, 2016Date of Patent: March 12, 2019Assignees: CUBE BIOTECH GmbH, QIAGEN GmbHInventors: Johann Kubicek, Frank Schaefer, Joerg Labahn, Georg Bueldt
-
Patent number: 10221445Abstract: The present invention refers to a method, a composition and a kit for isolating biomolecules from any biological sample material containing cells, virus(es), microorganism(s) or a combination thereof comprising a cell- or virus-simulating means, wherein said cell- or virus-simulating means comprises at least one type of marker molecule(s), incorporated in at least one type of a layer, capsule, bead, sphere or particle, which is not a biological cell or provided on a substrate covered by a coating.Type: GrantFiled: August 13, 2012Date of Patent: March 5, 2019Assignees: QIAGEN GmbH, QIAGEN Hamburg GmbHInventors: Katharina Beller, Thomas Doedt, Dirk Heckel, Rainer Söller
-
Patent number: 10184145Abstract: The present invention pertains to a method for isolating extracellular nucleic acids from a sample, wherein said sample is optionally stabilized, by binding the extracellular nucleic acids to a solid phase which carries anion exchange groups, comprising the following steps: binding the extracellular nucleic acids to the solid phase in a binding mixture having a first pH which allows binding the extracellular nucleic acids to the anion exchange groups of the solid phase; wherein the sample makes up at least 85% of the volume of the binding mixture; separating the solid phase with the bound extracellular nucleic acids; optionally washing the extracellular nucleic acids; optionally eluting extracellular nucleic acids from the solid phase. The method has the advantage that large sample volumes can be processed and that extracellular nucleic acids can be isolated rapidly with a high yield. The method is particularly suitable for automatable processes.Type: GrantFiled: September 25, 2012Date of Patent: January 22, 2019Assignee: QIAGEN GmbHInventors: Martin Horlitz, Annette Nocon, Markus Sprenger-Haussels, Peter Grünefeld, Christoph Erbacher